Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases Dr. Allen Davidoff, Chief Executive Officer of XORTX, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results